Pharmaceutical Product Monograph: Carboplatin Injection (150 mg, 450 mg, 600 mg)
In the pharmaceutical industry, Carboplatin is a second-generation platinum-based antineoplastic agent. As a pharmacist and manufacturer, I view this molecule as a “DNA Alkylator”—it is technically designed to provide a similar efficacy to Cisplatin but with a significantly improved safety profile regarding kidney toxicity (nephrotoxicity) and nausea.
At your WHO-GMP facility in Mumbai, Carboplatin is a high-value oncology SKU. Because its dosing is technically calculated using the Calvert Formula (based on GFR), understanding its side effect profile is critical for B2B clinical support.
The Most Common Side Effect: Myelosuppression
The most common and dose-limiting side effect of Carboplatin is Myelosuppression, specifically Thrombocytopenia (a dangerous drop in blood platelet counts).
| Side Effect | Clinical Presentation | Technical Rationale |
| Thrombocytopenia | Bleeding/Bruising | Most Common. Occurs in ~25% to 33% of patients; platelets typically reach their lowest point (nadir) at day 21. |
| Anemia | Fatigue/Pallor | Affects up to 70% of patients; cumulative over multiple cycles of chemotherapy. |
| Leukopenia | Infection Risk | A drop in white blood cells (Neutropenia) increases vulnerability to opportunistic infections. |
| Nausea & Vomiting | Emesis | Common but generally less severe than with Cisplatin; easily managed with modern anti-emetics. |
Mechanism: DNA Cross-Linking
Carboplatin works by creating “roadblocks” in the genetic material of rapidly dividing cancer cells:
Activation: Once inside the cell, the cyclobutane-dicarboxylate ligand is slowly displaced by water molecules (aquation).
Adduct Formation: The reactive platinum complex binds to the Guanine and Adenine bases of DNA.
Cross-Linking: It creates “Intrastrand Cross-links,” effectively “stapling” the DNA strands together.
Apoptosis: This prevents DNA replication and transcription. When the cell cannot repair this damage, it triggers programmed cell death (Apoptosis).
The Pharmacist’s “Technical Warning”
The “Platelet Nadir” Rule: As a pharmacist, I must emphasize that Carboplatin causes a delayed nadir. Unlike many other chemo drugs where blood counts drop at day 10, Carboplatin’s peak effect on platelets occurs between days 14 and 21.
The Calvert Formula: Dosing must be technically calculated based on the Area Under the Curve (AUC) and the patient’s Glomerular Filtration Rate (GFR):
$$\text{Total Dose (mg)} = (\text{target AUC}) \times (\text{GFR} + 25)$$Hypersensitivity: Risk increases after the 6th cycle. Patients may develop sudden rashes, itching, or shortness of breath (anaphylaxis) during infusion.
Ototoxicity: While lower than Cisplatin, it can still cause “ringing in the ears” (tinnitus) or high-frequency hearing loss.
The Manufacturer’s Perspective: Technical & Export
From a production and B2B standpoint at your facility in Mumbai:
The “Stable Solution” USP: Carboplatin is available as a ready-to-use (RTU) aqueous solution. On your digital marketplace, highlight your Oxy-Safe Filling process—Carboplatin is sensitive to aluminum; ensuring that no aluminum components (like needles or equipment) touch the solution is a technical requirement to prevent drug degradation.
Light Protection: The solution is light-sensitive. Utilizing Amber USP Type I glass vials ensures a 24-month shelf life.
Dossier Support: We provide full WHO-standard CTD/eCTD Dossiers for Carboplatin (multiple strengths) to support your registration in international oncology tenders.